LC-MS/MS를 이용한 혈청 중 dutasteride 분석
Analysis of dutasteride in human serum by LC-MS/MS
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
본 연구는 혈청 중 두타스테라이드의 확인과 정량을 위하여 LC-ESI-MS/MS를 이용한 신뢰성 있는 분석법을 개발하고, 분석방법의 타당도를 검증하고자 수행하였다. 내부표준물질인 베클로메타손을 첨가한 혈청을 methyl tert-butyl ether (MTBE)를 사용하여 액체상추출법(liquid-liquid extraction, LLE)으로 추출하였다. LC-MS/MS의 양이온 모드에서 MRM(multiple reaction monitoring)방법으로 확인한 두타스테라이드와 베클로메타손의 mass transition은 각각 m/z 529.6→461.5, m/z 409.3→391.2 이었으며, 머무름 시간은 각각 6.45분, 5.46분이었다. 검량선은 0.5~30.0 ng/mL의 농도 범위에서 R2=0.9999의 높은 직선성을 나타내었으며, 정량한계와 회수율은 각각 0.5 ng/mL와 66~72% 이었다. 일내에 대한 정밀도는 3.5~5.5%, 정확도는 85.7~89.9% 범위이었으며, 연속 3일간 수행한 일간 정밀도는 4.2~5.8%, 정확도는 90.8~95.8% 이었다.
Abstract
The determination and confirmation of dutasteride in human serum was performed by a liquid chromatography-electrospray ionization tandem mass spectrometry (LC-ESI/MS/MS). Beclomethasone as an internal standard (I.S.) was added to the serum and the mixed sample was pretreated by liquid-liquid extraction (LLE) with methyl tert-butyl ether (MTBE). The mass transitions of dutasteride and I.S. monitored in multiple reaction monitoring (MRM) were m/z 529.6→461.5 and m/z 409.3→391.2, respectively, and the retention times were 6.45 and 5.46min, respectively. The calibration curve was linear in the concentration range of 0.5~30.0 ng/mL (R2= 0.9999) and the limit of quantitation (LOQ) was found to be 0.5 ng/mL. The recovery of dutasteride was shown to be 66~72%. The intra-day assay precision and accuracy were in the range 3.5~5.5% and 85.7~89.9%, respectively, and the interday assay precision and accuracy were in the range 4.2~5.8% and 90.8~95.8%, respectively
참고문헌 (21)
- C. G. Roehrborn, , Urol, 60, pp.434~441 (2002)
- H. C. Evans, , Drugs Aging, 20(12), pp.905~916 (2003)
- K. K. Gaines, , Urol. Nurs, 23(3), pp.218~220 (2003)
- G. L. Andriole, , Eur. Urol, 44, pp.82~88 (2003)
- F. Debruyne, , Eur. Urol., 46(4), pp.488~495 (2004)
- R. V. Clark, , J. Clin. Endocrinol Metab, 89(5), pp.2179~1284 (2004)
- E. A. Olsen, , J. AM ACAD DERMATOL, 55(6), pp.1014~1026 (2006)
- M. Marberger, , J. Clin. Endocrinol. Metab, 91(4), pp.1323~1328 (2006)
- C. G. Roehrborn, , J. Urol, 179(2), pp.616~621 (2008)
- J. C. Nickel, , Urol, 6(9), pp.S31~S39 (2004)
- N. Makridakis, , J. Mol. Endocrinol, 34, pp.617~623 (2005)
- J. K. Amory, , J. Clin. Endocrinol. Metab, 92(5), pp.1659~1665 (2007)
- C. L. Foley, , Drugs. Today, 40(3), pp.213~ (2004)
- A. M. Traish, , J. Sexual. Medicine, 8(3), pp.872~884 (2011)
- "Blood Guidances", Food and Drug Administration, ~ (2011)
- "Blood Regulation Law", Ministry of Health and Welfare, ~ (2011)
- N. V. S. Ramakrishna, , J. Chromatogr B, 809(1), pp.117~124 (2004)
- S. Agarwal, , Chromatographia, 67, pp.893~903 (2008)
- N. A. Gomes, , Chromatographia, 69, pp.9~18 (2009)
- "Bioanalytical Method Validation", National Institute of Food and Drug Safety Evaluation, ~ (2009)
- "Guidance for Industry, Bioanalytical Method Validation", Food and Drug Administration, ~ (2001)